AI CuratorAI-generated

Research summary · 4 d ago

AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

Projected Changes in Disease-Modifying Therapies for MS in Italy

Projections indicate the number of patients with MS treated by disease-modifying therapies (DMTs) in Italy will rise to around 77,000 by 2029, up by 10% from 2024. A decrease in traditional therapies is expected, while new therapies like BTK inhibitors may capture a 16% share soon after launching. Overall DMT expenditure is predicted to drop from €784 million in 2024 to €622 million in 2029.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42828703)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

These findings highlight a significant shift in MS treatment patterns toward new, potentially more effective therapies. The decline in spending suggests changes in the market and therapeutic strategies, which could impact healthcare costs and patient access to treatment.

What this does not prove

This study does not offer clinical outcomes or efficacy data for the therapies projected. The estimates are based on models and expert opinions rather than direct clinical evidence.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: Not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-03
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceHorizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model. ↗DOI: 10.1007/s40120-026-01042-7

Supporting passages (5)

study phaseMETHODS: Building on a published horizon-scanning model (i.e., Oracle), this study updates projections of expenditure and treatment patterns for MS DMTs through 2029, integrating clinical inputs (i.e., treated patients, patient shares for each reimbursed therapy) with economic inputs (i.e., annual therapy costs).

interventionThe objective of the present research is to estimate the Italian NHS expenditure for MS disease-modifying therapies (DMTs) between 2025 and 2029.

findingsRESULTS: This study shows that the number of treated patients is projected to rise to about 77,000 by 2029, i.e., approximately + 10% from 2024.

publication datePublication date: 2026-10-03

limitationsTitle: Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.